Again, prostate cancer confusion continues to reign. A recent study reported at the ASTRO (American Society for Radiation Oncology) conference claims that the addition of androgen deprivation therapy (ADT) in men with clinically localized prostate cancer was not associated with increased cardiovascular mortality. According to Jason A. Efstathiou, MD, Ph.D.l, of the Massachusetts General Hospital [...]
A recent article in the journal Cancer reported that there is an association for men being treated for prostate cancer with androgen deprivation therapy (ADT) and a risk of developing blood clots. The article, written by Edhaie et al. analyzed the Surveillance, Epidemiology and End Results (SEER) –Medicare database to identify 154,611 men over the [...]
Initially, when first used by Huggins and Hodges hormone therapy (ADT) was recommended to be used early on in prostate cancer disease progression. Eventually, the Veterans Administration Cooperative Urology Research Group (VACURG) studies reversed this early recommendation. After this study ADT was usually deferred until symptomatic progression. It was believed that ADT caused an alteration [...]
In today's issue of Cancer Discovery a group of international researchers report that an investigational drug had a dramatic response in animal models of neuroendocrine prostate cancer, a lethal form of the disease. The researchers pointed out that fewer than 2% of prostate tumors in men are initially diagnosed as neuroendocrine, but many of the [...]
A group of researchers just reported positive results of a phase 3 trial showing that the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer (T3 & T4) to androgen deprivation therapy (ADT) alone. The researchers used a sample of 1,057 men with locally advanced (T3 or T4) prostate [...]